Magnetar Financial LLC Buys Shares of 160,571 Bruker Corporation $BRKR

Key Points

• Magnetar Financial LLC acquired approximately $6.70 million worth of 160,571 shares in Bruker Corporation, representing about 0.11% of the company's stock.
• Bruker reported a net margin of 2.31% and revenue of $797.40 million for the last quarter, which was below analyst expectations.
• The company's stock has been rated by analysts with five "Buy" ratings and six "Hold" ratings, with a current consensus target price of $51.30.

Magnetar Financial LLC purchased a new position in Bruker Corporation (NASDAQ:BRKR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 160,571 shares of the medical research company's stock, valued at approximately $6,702,000. Magnetar Financial LLC owned about 0.11% of Bruker as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. purchased a new stake in shares of Bruker in the 1st quarter worth approximately $29,000. Allworth Financial LP boosted its position in Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after purchasing an additional 745 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Bruker during the first quarter valued at approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in Bruker by 274.9% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BRKR shares. Barclays dropped their price target on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. The Goldman Sachs Group reduced their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. UBS Group dropped their target price on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, Bank of America reduced their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $51.30.

Bruker Stock Performance

NASDAQ BRKR traded down $0.75 on Tuesday, hitting $33.23. 1,637,144 shares of the stock were exchanged, compared to its average volume of 2,439,086. Bruker Corporation has a 52 week low of $30.00 and a 52 week high of $72.94. The company has a market capitalization of $5.04 billion, a PE ratio of 63.91, a P/E/G ratio of 2.79 and a beta of 1.22. The business's fifty day moving average is $37.95 and its 200 day moving average is $40.08. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business's revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Research analysts anticipate that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was purchased at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 27.30% of the company's stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.